Trial reportPsychopharmacology2013
The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole.
Trial report in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis ofPsychological medicine · 2023Pooled it
- Brain-imaging studies of treatment-resistant schizophrenia: a systematic review.The lancet. Psychiatry · 2016Pooled it
- An investigation into aripiprazole's partial D₂ agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers.Psychopharmacology · 2016Trial
- Effects of amisulpride on human resting cerebral perfusion.Psychopharmacology · 2013Trial
- The Molecular Machinery of Synaptic Plasticity and Its Potential Role in the Aetiology of Schizophrenia.Molecular neurobiology · 2026Review
- Negative association between cognitive functioning and antipsychotic DPsychological medicine · 2026Article
- The sense and nonsense of antipsychotic combinations: A model for dopamine DTranslational psychiatry · 2025Article
- Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice.Frontiers in psychiatry · 2022Review
- Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Preservation of brain metabolism in recently diagnosed Parkinson's impulse control disorders.European journal of nuclear medicine and molecular imaging · 2020Article
- Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development.European journal of nuclear medicine and molecular imaging · 2020Review
- Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models.Frontiers in neuroscience · 2020Review
- Long-term Effects of Aripiprazole Treatment during Adolescence on Cognitive Function and Dopamine D2 Receptor Expression in Neurodevelopmentally Normal Rats.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2019Article
- Brain Networks Reveal the Effects of Antipsychotic Drugs on Schizophrenia Patients and Controls.Frontiers in psychiatry · 2019Article
- The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [Translational psychiatry · 2018Article
- Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.CNS drugs · 2018Review
- Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study.Neuropsychiatric disease and treatment · 2018Article
- Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2018Review
- Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome.Scientific reports · 2017Article
- Gray matter increases in fronto-parietal regions of depression patients with aripiprazole monotherapy: An exploratory study.Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
rationaleThe effects of aripiprazole on cognitive function are obscure, possibly due to the difficulty in disentangling the specific effects on cognitive function from effects secondary to the improvement of other schizophrenic symptoms. This prompts the necessity of using an intermediate biomarker relating the drug effect on the brain to change in cognitive function.
objectivesTo explore the effect of aripiprazole on cognitive function, we measured changes in frontal metabolism as an intermediate biomarker and sought to determine its relationship with D2 receptor occupancy and changes in working memory.
methodsFifteen healthy male volunteers participated in the study. Serial positron emission tomography (PET) scans with [(11)C]raclopride and [(18) F]FDG were conducted 1 day before and 2 days after the administration of aripiprazole. The subjects performed the N-back task just after finishing the [(18) F]FDG scan.
resultsThe mean (±SD) D2 receptor occupancies were 22.2 ± 16.0 % in the 2 mg group, 35.5 ± 3.6 % in the 5 mg group, 63.2 ± 9.9 % in the 10 mg group and 72.8 ± 2.1 % in the 30 mg group. The frontal metabolism was significantly decreased after the administration of aripiprazole (t = 2.705, df = 14, p = 0.017). Greater striatal D2 receptor occupancy was related to greater decrease in frontal metabolism (r = -0.659, p = 0.010), and greater reduction in frontal metabolism was associated with longer reaction times (r = -0.597, p = 0.019) under the greatest task load.
conclusionsAripiprazole can affect cognitive function and alter frontal metabolic function. The changes in these functions are linked to greater D2 receptor occupancy. This suggests that it may be important to find the lowest effective dose of aripiprazole in order to prevent adverse cognitive effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.